Abbott Laboratories (ABT) has garnered significant attention among investors and analysts. TV personality Jim Cramer has particularly voiced his confidence, suggesting it's misunderstood due to its innovative work on diabetes. The company has shown solid performance with a new 12-month high and a reported 43% return over the past five years. There are fluctuations in shareholding across several financial entities, with some, like Rep. Emily Randall and Rep. Josh Gottheimer, selling and buying significant amounts of stock respectively. However, investor interest remains high as Asset Planning Inc, Bank Pictet & Cie Europe AG, and others, have invested in Abbott. The recent Q4 earnings were in line with estimates exhibiting steady growth. Negative outcomes include being rated a "moderate buy" by analysts and a cautious approach suggested by some due to insider selling. Yet, the medical device sector performance and Legacy Hill Capital’s preference indicate potential. Abbott's legal issues have been presented as non-threatening. Their 2025 financial outlook following the Q4 2024 earnings and the sales forecast impresses. The consideration by investors and positive rating against an RS benchmark underline market faith.
Abbott Laboratories ABT News Analytics from Tue, 27 Aug 2024 07:00:00 GMT to Sat, 15 Feb 2025 17:19:42 GMT -
Rating 3
- Innovation 5
- Information 7
- Rumor -2
